Future of GLP-1 receptor agonists In a related editorial, Thiara noted that although Tang and colleagues found that GLP-1 receptor agonists and SGLT2 inhibitors had a similar effect on ADRD, the team did show that isolating semaglutide, the newest and most potent GLP-1 receptor agonist on the market, showed decreased risk of ADRD compared with SGLT2 inhibitors. Both studies had limitations, including short-term follow-up, low dementia event rates and confounding variables, Thiara wrote
PubMed Rena G, Hardie DG, Pearson ER
Wait a secdid you say LESS meds
Beneficial for athletes and active individuals
A qualified provider reviews your medical history, BMI, and lab work to confirm you are a good candidate, then starts you at a low weekly dose (typically 0.25 mg) and increases it gradually over several months
Kahn explains